{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:14Z","timestamp":1759336574952,"version":"build-2065373602"},"reference-count":25,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Porphyria cutanea tarda (PCT) is caused by decreased activity of uroporphyrinogen decarboxylase (UROD) due to various susceptibility factors, here among pathogenic variants in UROD and the presence of iron overload. Porphyrins are sensitive to light and cause cutaneous symptoms in the form of blisters and ulcers on sun-exposed skin. This review gives an update on diagnosing, monitoring and the treatment of PCT. PCT is often effectively treated with venesection or\/and low-dose hydroxychloroquine. Additionally, patients must be informed about sufficient sun protection and reduction of susceptibility factors.<\/jats:p>","DOI":"10.61409\/v11240832","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T10:36:11Z","timestamp":1758105371000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Porphyria cutanea tarda"],"prefix":"10.61409","author":[{"given":"Josephine","family":"Misteg\u00e5rd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Lindegaard","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Christian","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik F.","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Christiansen AL, Aagaard L, Krag A et al. Cutaneous porphyrias: causes, symptoms, treatments and the Danish incidence 1989-2013. Acta Derm Venereol. 2016;96(7):868-872. https:\/\/doi.org\/10.2340\/00015555-2444","DOI":"10.2340\/00015555-2444"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Christiansen AL, Lorentzen H, Fruekilde PBN, Frystyk J. 04141 investigation for porphyria in Denmark. BMJ Open Gastroenterol. 2024;11(Suppl 1):A41-A42. https:\/\/doi.org\/10.1136\/bmjgast-2024-ICPP.74","DOI":"10.1136\/bmjgast-2024-ICPP.74"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Plavskii VY, Mikulich AV, Tretyakova AI et al. Porphyrins and flavins as endogenous acceptors of optical radiation of blue spectral region determining photoinactivation of microbial cells. J Photochem Photobiol B. 2018;183:172-183. https:\/\/doi.org\/10.1016\/j.jphotobiol.2018.04.021","DOI":"10.1016\/j.jphotobiol.2018.04.021"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Phillips JD. Heme biosynthesis and the porphyrias. Mol Genet Metab. 2019;128(3):164-177. https:\/\/doi.org\/10.1016\/j.ymgme.2019.04.008","DOI":"10.1016\/j.ymgme.2019.04.008"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem. 2009;55(4):795-803. https:\/\/doi.org\/10.1373\/clinchem.2008.117432","DOI":"10.1373\/clinchem.2008.117432"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019;128(3):271-281. https:\/\/doi.org\/10.1016\/j.ymgme.2019.01.004","DOI":"10.1016\/j.ymgme.2019.01.004"},{"key":"ref6","unstructured":"Milman NT, Schi\u00f8dt FV, Junker AE et al. Genetisk HFE-h\u00e6mochromatose. Ugeskr L\u00e6ger. 2018;180(51):V09180619. https:\/\/ugeskriftet.dk\/videnskab\/genetisk-hfe-haemokromatose"},{"key":"ref7","unstructured":"Gocmen A, Peters HA, Cripps DJ et al. Hexachlorobenzene episode in Turkey. Biomed Environ Sci. 1989;2(1):36-43"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood. 2012;120(23):4496-504. https:\/\/doi.org\/10.1182\/blood-2012-05-423186","DOI":"10.1182\/blood-2012-05-423186"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Handler NS, Handler MZ, Stephany MP et al. Porphyria cutanea tarda: an intriguing genetic disease and marker. Int J Dermatol. 2017;56(6):e106-e117. https:\/\/doi.org\/10.1111\/ijd.13580","DOI":"10.1111\/ijd.13580"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Sarkany RPE, Phillips JD. The clinical management of porphyria cutanea tarda: an update. Liver Int. 2024;44(9):2191-2196. https:\/\/doi.org\/10.1111\/liv.15980","DOI":"10.1111\/liv.15980"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Aarsand AK, To-Figueras J, Whatley S et al. Practical recommendations for biochemical and genetic diagnosis of the porphyrias. Liver Int. 2025;45(3):e16012. https:\/\/doi.org\/10.1111\/liv.16012","DOI":"10.1111\/liv.16012"},{"key":"ref12","unstructured":"NAPOS. Porphyria cutanea tarda (PCT) retningslinjer for behandling og oppf\u00f8lgning, 2023. https:\/\/www.helse-bergen.no\/4a5e77\/siteassets\/seksjon\/napos\/dokum.-fra-tidl.-losning\/behandlingsretningslinjer-for-porphyria-cutanea-tarda-pct.pdf (26. nov 2024)"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Nyckowski T, Grammenos A, Vinokurov A, Nathoo R. Between a rock and a hard place: management of systemic lupus erythematosus and porphyria cutanea tarda. J Dermatolog Treat. 2022;33(5):2689-2691. https:\/\/doi.org\/10.1080\/09546634.2022.2060925","DOI":"10.1080\/09546634.2022.2060925"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Sarkell B, Patterson JW. Treatment of porphyria cutanea tarda of end-stage renal disease with erythropoietin. J Am Acad Dermatol. 1993;29(3):499-500. https:\/\/doi.org\/10.1016\/S0190-9622(08)82010-5","DOI":"10.1016\/S0190-9622(08)82010-5"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Gorman N, Zaharia A, Trask HS et al. Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology. 2007;46(6):1927-834. https:\/\/doi.org\/10.1002\/hep.21903","DOI":"10.1002\/hep.21903"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Sastre L, To-Figueras J, Lens S et al. Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals. Aliment Pharmacol Ther. 2020;51(10):968-973. https:\/\/doi.org\/10.1111\/apt.15703","DOI":"10.1111\/apt.15703"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Combalia A, To-Figueras J, Laguno M et al. Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda. Br J Dermatol. 2017;177(5):e183-e184. https:\/\/doi.org\/10.1111\/bjd.15502","DOI":"10.1111\/bjd.15502"},{"key":"ref18","unstructured":"Rocchi E, Gibertini P, Cassanelli M et al. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med. 1986;107(1):36-42"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Ratnaike S, Blake D, Campbell D et al. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. Australas J Dermatol. 1988;29(1):3-8. https:\/\/doi.org\/10.1111\/j.1440-0960.1988.tb01216.x","DOI":"10.1111\/j.1440-0960.1988.tb01216.x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Enr\u00edquez de Salamanca R, Rico R, Pe\u00f1a ML et al. Patterns of porphyrin excretion in porphyria cutanea tarda under venesection treatment. Int J Biochem. 1980;12(5-6):861-8. https:\/\/doi.org\/10.1016\/0020-711X(80)90175-5","DOI":"10.1016\/0020-711X(80)90175-5"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ibrahim AA, Esen UI. Porphyria cutanea tarda in pregnancy: a case report. J Obstet Gynaecol. 2004;24(5):574-5. https:\/\/doi.org\/10.1080\/01443610410001722716","DOI":"10.1080\/01443610410001722716"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Christiansen AL, Bygum A, Hother-Nielsen O, Rasmussen LM. Diagnosing diabetes mellitus in patients with porphyria cutanea tarda. Int J Dermatol. 2018;57(7):763-769. https:\/\/doi.org\/10.1111\/ijd.13938","DOI":"10.1111\/ijd.13938"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Baravelli CM, Sandberg S, Aarsand AK, Toll\u00e5nes MC. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet J Rare Dis. 2019;14(1):77. https:\/\/doi.org\/10.1186\/s13023-019-1051-3","DOI":"10.1186\/s13023-019-1051-3"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Edwards MV, Ray JM, Bacon BR. Sporadic porphyria cutanea tarda as the initial manifestation of hereditary hemochromatosis. ACG Case Rep J. 2019;6(11):e00247. https:\/\/doi.org\/10.14309\/crj.0000000000000247","DOI":"10.14309\/crj.0000000000000247"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:10:03Z","timestamp":1759327803000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V11240832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":25,"URL":"https:\/\/doi.org\/10.61409\/v11240832","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}